BioStar Capital-Backed Amplitude Vascular Systems’ $835M Acquisition by Stryker Reflects Strength of Michigan’s Medtech Ecosystem
BioStar Capital, a venture capital firm focused on transformative medical technologies, has announced a landmark pre-FDA exit of Amplitude Vascular Systems, Inc. (AVS), a medical technology company that created a next-generation hydraulic intravascular lithotripsy (IVL) platform to treat calcified peripheral arterial disease. Upon acquiring AVS for up to $835 million, Stryker (
NYSE:SYK), a global leader in medical technologies, called the deal a milestone in the expansion of its peripheral vascular portfolio.
BioStar Capital Closes Fund V at $130.3 Million, Surpassing Previous Funds
BioStar Capital, a strategic venture capital firm focusing on transformative medical technologies primarily in the fields of cardiovascular disease, orthopedics, and robotics, has announced it has closed its fifth fund at $130.3 million, more than its three previous funds combined.
Jeffrey Yau, PhD, VP of Data Science and Engineering at Walmart Global Technology, Joins BioStar Capital as Entrepreneur in Residence
BioStar Capital, a value-add investment firm focused on transformational medical device technologies that serve unmet patient and physician needs, today announced that Jeffrey Yau, PhD in Economics and VP of Data Science, Data Engineering, and Platform Engineering of Store Associate Tech at Walmart Global Technology, has joined the firm as an entrepreneur in residence (EIR). Dr. Yau was also previously Chief Data Scientist at AllianceBernstein, a global investment management and research firm with almost $700B in assets under management.
